AI Article Synopsis
- The study focused on creating a liquid self-microemulsifying drug delivery system (SMEDDS) for eprosartan mesylate, a poorly soluble drug, using specific surfactants and oil phases to enhance solubility and absorption.* -
- Various methods including phase diagram analysis and central-composite design were employed to optimize the formulation, and multiple parameters like particle size and drug release rates were measured to evaluate effectiveness.* -
- Results indicated that the SMEDDS formulation significantly improved the drug's release and bioavailability compared to traditional solid formulations, achieving a relative bioavailability increase of about 152% in rat studies.*
Article Abstract
Background: Formulations of eprosartan mesylate with a surfactant, like Kolliphor HS 15, an oil phase like Labrafil M 1944 CS, and a cosurfactant Transcutol HP by employing a liquid self-microemulsifying drug delivery system (SMEDDS) after screening several vehicles have been studied.
Objective: This study aimed to prepare a liquid self-microemulsifying drug delivery system for increasing the solubility and bioavailability of a poorly water-soluble eprosartan mesylate.
Methods: The micro-emulsion unit, achieved through the phase diagram and augmented with the central-composite design (CCD) surface response process, was adjusted into SMEDDS by lyophilization using sucrose as a cryoprotective agent. Particle size, self-emulsification time, polydispersion index (PDI), zeta potential, differential scanning calorimeter (DSC) screening, in-vitro drug release, and in-vivo pharmacokinetics were the essential features of the formulations. The subsequent DSC experimentation indicated that the drug was integrated into S-SMEDDS. Eprosartan mesylate loaded SMEDDS formulation showed greater in-vitro and in-vivo drug release than conventional solid doses.
Results: SMEDDS has reported effectiveness in reducing the impact of pH of eprosartan mesylate, thereby improving its release efficiency. The HPLC method was successfully implemented to assess eprosartan mesylate concentration in Wister rat plasma after oral administration of commercial tablet EM, SMEDDS, and eprosartan mesylate. The pharmacokinetics parameters for rats were C 1064.91 ± 225 and 1856.22 ± 749 ngmL, T 1.9 ± 0.3 hr, and 1.2 ± 0.4 hr and AUC were 5314.36 ± 322.61 and 7760.09 ± 249 ng/ml hr for marketed tablets and prepared SSMEDDS, respectively. When determined by AUC, the relative bioavailability of eprosartan mesylate S-SMEDDC was 152.09 ± 14.33%.
Conclusion: The present study reports the formulation of a self-microemulsifying drug delivery system for enhancing the solubility and bioavailability of a poorly water-soluble eprosartan mesylate in an appropriate solid dosage form.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/2211738510666220915100150 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Self-microemulsifying Drug Delivery System for Solubility and Bioavailability Enhancement of Eprosartan Mesylate: Preparation, , and Evaluation.
Pharm Nanotechnol
March 2023
SES's R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur Dist. Dhule (MS) 425 405, India.
Article Synopsis
- The study focused on creating a liquid self-microemulsifying drug delivery system (SMEDDS) for eprosartan mesylate, a poorly soluble drug, using specific surfactants and oil phases to enhance solubility and absorption.* -
- Various methods including phase diagram analysis and central-composite design were employed to optimize the formulation, and multiple parameters like particle size and drug release rates were measured to evaluate effectiveness.* -
- Results indicated that the SMEDDS formulation significantly improved the drug's release and bioavailability compared to traditional solid formulations, achieving a relative bioavailability increase of about 152% in rat studies.*
Formulation and characterization of eprosartan mesylate and β-cyclodextrin inclusion complex prepared by microwave technology.
Drug Deliv
December 2022
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
The goal of this work was to improve the aqueous solubility and dissolution rate of eprosartan mesylate by preparing inclusion complex of drug with β-cyclodextrin (β-CD) by microwave technique. In order to determine the solubility of eprosartan, phase solubility was determined and dissolution study was also conducted. Further, analytical techniques for instance, particle size distribution, differential scanning calorimetry, powder X-ray diffraction, scanning electron microscopy, Fourier-transform infrared spectroscopy, and nuclear magnetic resonance spectroscopy were used for the characterization of inclusion complex.
View Article and Find Full Text PDFFormulation and design optimization of nano-transferosomes using pioglitazone and eprosartan mesylate for concomitant therapy against diabetes and hypertension.
Eur J Pharm Sci
July 2021
Faculty of Pharmacy and Pharmaceutical Sciences, Katz Group Centre for Pharmacy & Health Research, University of Alberta, Edmonton, AB, Canada. Electronic address:
Hypertension, a form of cardiovascular diseases, is considered a major risk factor associated with deaths in type 2 diabetes patients. The current medication systems for treating such chronic coexisting diseases are limited and challenging due to the difficulties in overcoming the side effects from complex therapeutic and treatment regimen. The objective of the present study is to design and optimize pioglitazone (PIO) and eprosartan mesylate (EM)-loaded nano-transferosomes (NTs) using Design-Expert software, aiming its transdermal delivery as a novel combination therapy for concomitant treatment of hypertensive diabetic patients.
View Article and Find Full Text PDFHPLC method transfer study for simultaneous determination of seven angiotensin II receptor blockers.
J Sep Sci
April 2020
Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
In this study, a sensitive high-performance liquid chromatography method was developed and validated for the simultaneous determination of seven angiotensin II receptor blockers, namely, hydrochlorothiazide, chlorthalidone, eprosartan mesylate, valsartan, losartan potassium, irbesartan, and candesartan cilexetil. Different chromatographic parameters were tested and fully optimized. Best chromatographic separation was accomplished on a reversed-phase octadecylsilyl column (250 × 4.
View Article and Find Full Text PDFRisk assessment and QbD based optimization of an Eprosartan mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment.
Int J Pharm
August 2019
Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, India. Electronic address:
Quality by design (QbD) principles were implemented to understand the product and process variables of sonoprecipitation technique, for preparation of eprosartan mesylate (EM) nanosuspension. Quality risk management approach was utilized to identify and assess high-risk attributes affecting critical quality attributes (CQA's), prioritizing the number of experiments. The effect of critical material attributes (CMA's) and critical process parameters (CPP's) (soluplus concentration, drug concentration ultrasonication amplitude) on z-average particle size and PDI were investigated using a central composite face-centered design (CCF).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!